| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.043 | 0.4 |
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.4 |
| mRNA | QL-X-138 | GDSC1000 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.044 | 0.4 |
| mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | FR-180204 | GDSC1000 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | -0.04 | 0.4 |